On Monday, Seres Therapeutics Inc (MCRB) stock saw a decline, ending the day at $0.81 which represents a decrease of $-0.01 or -1.22% from the prior close of $0.82. The stock opened at $0.83 and ...

Seres Therapeutics, Inc. (MCRB) Q2 2024 Earnings Call Transcript Seres Therapeutics jumps on report of Nestle acquisition ...

Seres Therapeutics (NASDAQ:MCRB) rose 7% on a report that Nestle (OTCPK:NSRGY) made an acquisition offer for the company that ...

On Tuesday, Seres Therapeutics Inc (MCRB) stock saw a modest uptick, ending the day at $0.77 which represents a slight increase of $0.07 or 10.00% from the prior close of $0.7. The stock opened at $0.

Prominent players in the human microbiome market are Seres Therapeutics, Inc. (US), Enterome (France), 4D pharma plc (UK), ...

View Seres Therapeutics, Inc. (MCRB) current and estimated P/E ratio data provided by Seeking Alpha.

Oppenheimer analyst Jeff Jones maintained a Buy rating on Pliant Therapeutics (PLRX – Research Report) today and set a price target of ...

Short interest in Seres Therapeutics Inc (NASDAQ:MCRB) increased during the last reporting period, rising from 15.94M to 17.22M. This put 15.76% of the company's publicly available shares short.

Oppenheimer analyst Jeff Jones maintained a Buy rating on Ventyx Biosciences (VTYX – Research Report) today and set a price target of ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Long-term investors should consider making these Fidelity mutual funds the core of their portfolio.